These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21792901)

  • 61. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.
    Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F
    J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.
    Sadanaga N; Nagoshi M; Lederer JA; Joo HG; Eberlein TJ; Goedegebuure PS
    J Immunother; 1999 Jul; 22(4):315-23. PubMed ID: 10404433
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Virus-Specific CD8
    Erkes DA; Smith CJ; Wilski NA; Caldeira-Dantas S; Mohgbeli T; Snyder CM
    J Immunol; 2017 Apr; 198(7):2979-2988. PubMed ID: 28202614
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas.
    Cózar JM; Canton J; Tallada M; Concha A; Cabrera T; Garrido F; Ruiz-Cabello Osuna F
    Cancer Immunol Immunother; 2005 Sep; 54(9):858-66. PubMed ID: 15887015
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
    Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
    Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
    Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes.
    Ma D; Alizadeh H; Comerford SA; Gething MJ; Sambrook JF; Anand R; Niederkorn JY
    Curr Eye Res; 1994 May; 13(5):361-9. PubMed ID: 7914482
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Local injections of OK432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Th1-type cytokines and CXC3 chemokines.
    Tatsugami K; Tamada K; Abe K; Harada M; Nomoto K
    Cancer Immunol Immunother; 2000 Sep; 49(7):361-8. PubMed ID: 10999462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reduced CD5 on CD8
    Alotaibi F; Vincent M; Min WP; Koropatnick J
    Front Immunol; 2020; 11():584937. PubMed ID: 33584650
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
    Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
    Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.
    Sektioglu IM; Carretero R; Bulbuc N; Bald T; Tüting T; Rudensky AY; Hämmerling GJ
    Cancer Res; 2017 Jan; 77(2):291-302. PubMed ID: 27879269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.